UNOVARTIS

Aimovig - Injection training video - MOP Image



Image

Aimovig® (erenumab)

Aimovig injection training video

This page is specifically intended to support patients who have been prescribed Aimovig (erenumab) by a UK healthcare provider. If you have any questions about your medication, ask your doctor, nurse or pharmacist and read the patient information leaflet provided with your medicine.



This video is intended for patients who have been prescribed Aimovig (erenumab) for migraines. Aimovig is used to prevent migraine in adults who have at least 4 migraine days per month when starting treatment with Aimovig. Please read the patient information leaflet for Aimovig 70 mg or 140 mg pre-filled pen provided with your medicine carefully, as it contains important additional information about what you need to know before you start treatment. This video does not replace the instructions and important additional information in the patient information leaflet.

Reporting of side effects.

If you get side-effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side-effects not listed in the information leaflet that comes in the pack. You can report side-effects via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side-effects you can help provide more information on the safety of your medication.

Please see www.mhra.gov.uk/yellowcard for instructions on how to report side effects. This video is developed and funded by Novartis Pharmaceuticals UK.



UK | January 2024 | 400906

VIDEO

More information about Aimovig

Summary of Product Characteristics (SmPC) for Aimovig

Patient Information Leaflet (PIL) for Aimovig

These links will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

UK | January 2025 | FA-11330669

Reporting side-effects

If you get side-effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side-effects not listed in the information leaflet that comes in the pack. You can report side-effects via the Yellow Card Scheme at <u>www.mhra.gov.uk/yellowcard</u>.

By reporting side-effects you can help provide more information on the safety of your medication.

Source URL:

https://www.pro.novartis.com/uk-en/public/medicines/neuroscience/aimovig/patient-resourc es/injection-training